Short answer
Nuvation Bio Inc. (NUVB) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Nuvation Bio reported financial results for quarter ended March 31, 2026.
Nuvation Bio Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Nuvation Bio reported financial results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1 contains the results and management disclosures
- Information furnished under Item 2.02, not deemed filed under Section 18 or incorporated by reference unless specifically referenced
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue reached $83.2M, including $18.5M IBTROZI product sales and $64.7M collaboration revenue
- Net income $5.4M, or $0.02 basic EPS, versus $53.2M net loss in Q1 2025
- IBTROZI added approximately 200 new patients in Q1, with over 600 treated since its June 2025 launch
- TKI-naïve patients showed 89.8% response rate, 49.7-month response duration, and 46.1-month progression-free survival
- Cash, equivalents, and marketable securities totaled $533.7M, supporting global safusidenib development and pipeline investment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Nuvation Bio Inc. 8-K filings
Get the next NUVB 8-K as it lands
Follow NUVB for push alerts, or ask the research agent what this filing means.